Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1061-1070 of 1,873) with videos related to

Pageof 188
Sort By:
European Journal of Heart Failure|November 17, 2017
Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trialMuthiah Vaduganathan, Baljash Cheema, Erin Cleveland, et al.
Circulation. Heart Failure|December 16, 2017
Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community SurveillanceTonje Thorvaldsen, Brian L Claggett, Amil Shah, et al.
JACC. Cardiovascular Imaging|April 10, 2009
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic StudyAnil Verma, Alessandra Meris, Hicham Skali, et al.
JAMA Cardiology|March 4, 2026
Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities StudyMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
European Heart Journal|April 4, 2017
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) studyBurkert Pieske, Aldo P Maggioni, Carolyn S P Lam, et al.
European Heart Journal. Cardiovascular Imaging|July 3, 2024
Cardiac mechanics and the risk of atrial fibrillation in a community-based cohort of older adultsRiccardo M Inciardi, Wendy Wang, Alvaro Alonso, et al.
European Journal of Heart Failure|October 30, 2015
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristicsHenry Krum, John J V McMurray, William T Abraham, et al.
European Journal of Heart Failure|July 27, 2022
Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trialSafia Chatur, Muthiah Vaduganathan, Alexander Peikert, et al.
European Journal of Heart Failure|July 17, 2019
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristicsJohn J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Journal of the American Heart Association|April 25, 2016
Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marwa A Sabe, Brian Claggett, Emmanuel A Burdmann, et al.
Pageof 188

Showing results (1061-1070 of 1,873) with videos related to

Sort By:
Pageof 188
European Journal of Heart Failure|November 17, 2017
Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trialMuthiah Vaduganathan, Baljash Cheema, Erin Cleveland, et al.
Circulation. Heart Failure|December 16, 2017
Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community SurveillanceTonje Thorvaldsen, Brian L Claggett, Amil Shah, et al.
JACC. Cardiovascular Imaging|April 10, 2009
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic StudyAnil Verma, Alessandra Meris, Hicham Skali, et al.
JAMA Cardiology|March 4, 2026
Spectrum of Primary Aldosteronism and Risk of Cardiovascular Outcomes: The Atherosclerosis Risk in Communities StudyMats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
European Heart Journal|April 4, 2017
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) studyBurkert Pieske, Aldo P Maggioni, Carolyn S P Lam, et al.
European Heart Journal. Cardiovascular Imaging|July 3, 2024
Cardiac mechanics and the risk of atrial fibrillation in a community-based cohort of older adultsRiccardo M Inciardi, Wendy Wang, Alvaro Alonso, et al.
European Journal of Heart Failure|October 30, 2015
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristicsHenry Krum, John J V McMurray, William T Abraham, et al.
European Journal of Heart Failure|July 27, 2022
Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trialSafia Chatur, Muthiah Vaduganathan, Alexander Peikert, et al.
European Journal of Heart Failure|July 17, 2019
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristicsJohn J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Journal of the American Heart Association|April 25, 2016
Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marwa A Sabe, Brian Claggett, Emmanuel A Burdmann, et al.
Pageof 188